HeartSciences Inc.

HeartSciences Inc. is a healthcare information technology company that focuses on improving electrocardiography (ECG or EKG) by incorporating artificial intelligence (AI). The company's primary commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform. This platform aims to modernize ECG workflows and allow for the widespread use of AI-ECG capabilities within healthcare systems. MyoVista Insights™ is categorized as a Medical Device Data System (MDDS) and is exempt from FDA 510(k) requirements. The platform is designed to organize ECG studies, improve waveform analysis, and simplify clinical workflows, leading to more efficient interpretation, storage, and management of ECG data. It can also host AI-ECG algorithms from various vendors and integrate them into clinical workflows, providing a flexible base for AI adoption in ECG. After an early adopter launch in 2025, phased enhancements were implemented. In March 2026, a significant version upgrade was released for broader deployment in cardiology and healthcare IT environments. This upgrade included mobile device access, improved reporting, and expanded interoperability for integration across large health systems. In March 2026, MyoVista Insights™ received Epic Toolbox designation for the ECG Management System category from Epic Systems Corporation. The company expects to generate revenue from installation fees, software-as-a-service (SaaS) usage fees, and fees for AI-ECG algorithms available through the platform's AI-ECG marketplace, including third-party algorithms. HeartSciences Inc. has also developed the MyoVista® wavECG™ device, which offers conventional ECG functionality and is designed to host embedded AI-ECG algorithms. This device was submitted to the FDA for 510(k) premarket clearance in December 2025 and is currently under FDA review.